Backed by Years of Research The ResQGARD has been evaluated in over 30 animal and clinical studies, many done in collaboration with, and supported by, the US Department of Defense. This research has shown that the ResQGARD3-9: C omplements a permissive hypotension approach in trauma without exceeding pressures typically associated with “popping the clot” Increases stroke volume, cardiac output, and cerebral blood flow Lowers intracranial pressure during inspiration Is well tolerated by most patients Does not compromise oxygen saturation or reduce hematocrit “Buys time” until definitive therapy can be provided Increases systolic and diastolic blood pressure by up to 30% In 2008, the ResQGARD received the US Army’s SBIR Achievement Award for the technology’s application in the non-invasive treatment of hemorrhagic shock. How to Order: To place an order for ResQGARD, call toll-free 877-737-7763. Product # 12-0707-000 Product # 12-0706-000 Product # 12-0392-000 Compatible with facemask or mouthpiece Allows for administration of supplemental oxygen Latex-free Single-patient use ResQGARD FM (Facemask) Kit ResQGARD Military Kit (US only); NSN #6515-01-575-8173 ResQSTRAP Jones, et al. Chest. 2006;130:941-946. Eastridge, et al. J Trauma. 2007;63:291-299. Smith, et al. J Emerg Med. 2011;41(5):549-558. Convertino, et al. Respir Care. 2011;56(6):846-857. Suresh, et al. Prehosp Emerg Care. 2012;16(1):173. Convertino, et al. Crit Care Med. 2007;35(4):1145-1152. Cook, et al. J Trauma. 2006;60(6):1275-1283. Metzger, et al. Prehosp Emerg Care. 2012;16:174. Yannopoulos, et al. Crit Care Med. 2006;34(12):S495-500. The generally cleared indication for the ResQGARD is for a temporary increase in blood circulation during emergency care, hospital, clinic, and home use. Research is ongoing to evaluate the benefit of the ResQGARD for indications related to specific etiologies. The studies listed here are not intended to imply specific outcome-based claims not yet cleared by the US FDA. An Asahi Kasei Group Company | 269 Mill Road | Chelmsford, MA 01824 | 800-804-4356 | www.zoll.com Copyright © 2016 ZOLL Medical Corporation. All rights reserved. ResQGARD and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All other trademarks are the property of their respective owners. MCN CRP 1608 0039 For subsidiary addresses and fax numbers, as well as other global locations, please go to www.zoll.com/contacts. RAPID, NON-INVASIVE

F or every 10 mmHg decrease in systolic blood pressure, mortality in hypotensive patients increases almost 5%.2 H ypotension accounts for nearly 20% of all hospital admissions from the ED.1 The ResQGARD® impedance threshold device (ITD) is clinically proven to be a safe, simple, and convenient alternative to treating spontaneously breathing patients with hypotension from a variety of causes, including: • • • • Blood loss or blood donation Dehydration Early sepsis Drug overdose E mergency department (ED) patients with hypotension are 2.5 times more likely to die in the hospital and 10 times more...

F or every 10 mmHg decrease in systolic blood pressure, mortality in hypotensive patients increases almost 5%.2 H ypotension accounts for nearly 20% of all hospital admissions from the ED.1 The ResQGARD® impedance threshold device (ITD) is clinically proven to be a safe, simple, and convenient alternative to treating spontaneously breathing patients with hypotension from a variety of causes, including: • • • • Blood loss or blood donation Dehydration Early sepsis Drug overdose E mergency department (ED) patients with hypotension are 2.5 times more likely to die in the hospital and 10 times more...

F or every 10 mmHg decrease in systolic blood pressure, mortality in hypotensive patients increases almost 5%.2 H ypotension accounts for nearly 20% of all hospital admissions from the ED.1 The ResQGARD® impedance threshold device (ITD) is clinically proven to be a safe, simple, and convenient alternative to treating spontaneously breathing patients with hypotension from a variety of causes, including: • • • • Blood loss or blood donation Dehydration Early sepsis Drug overdose E mergency department (ED) patients with hypotension are 2.5 times more likely to die in the hospital and 10 times more...

Backed by Years of Research The ResQGARD has been evaluated in over 30 animal and clinical studies, many done in collaboration with, and supported by, the US Department of Defense. This research has shown that the ResQGARD3-9: C omplements a permissive hypotension approach in trauma without exceeding pressures typically associated with “popping the clot” Increases stroke volume, cardiac output, and cerebral blood flow Lowers intracranial pressure during inspiration Is well tolerated by most patients Does not compromise oxygen saturation or reduce hematocrit “Buys time” until definitive therapy...

Backed by Years of Research The ResQGARD has been evaluated in over 30 animal and clinical studies, many done in collaboration with, and supported by, the US Department of Defense. This research has shown that the ResQGARD3-9: C omplements a permissive hypotension approach in trauma without exceeding pressures typically associated with “popping the clot” Increases stroke volume, cardiac output, and cerebral blood flow Lowers intracranial pressure during inspiration Is well tolerated by most patients Does not compromise oxygen saturation or reduce hematocrit “Buys time” until definitive therapy...